PDSB vs. AMLX, ACET, SGMT, KPTI, RNAC, CTXR, SCTL, GLYC, VTGN, and RPTX
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Amylyx Pharmaceuticals (AMLX), Adicet Bio (ACET), Sagimet Biosciences (SGMT), Karyopharm Therapeutics (KPTI), Cartesian Therapeutics (RNAC), Citius Pharmaceuticals (CTXR), Societal CDMO (SCTL), GlycoMimetics (GLYC), Vistagen Therapeutics (VTGN), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical preparations" industry.
PDS Biotechnology (NASDAQ:PDSB) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.0% of PDS Biotechnology shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
PDS Biotechnology presently has a consensus target price of $17.33, indicating a potential upside of 331.18%. Amylyx Pharmaceuticals has a consensus target price of $32.67, indicating a potential upside of 1,592.57%. Given Amylyx Pharmaceuticals' higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than PDS Biotechnology.
PDS Biotechnology received 33 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 66.28% of users gave PDS Biotechnology an outperform vote while only 63.16% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amylyx Pharmaceuticals has a net margin of 12.94% compared to PDS Biotechnology's net margin of 0.00%. Amylyx Pharmaceuticals' return on equity of 12.39% beat PDS Biotechnology's return on equity.
In the previous week, PDS Biotechnology and PDS Biotechnology both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 0.39 beat PDS Biotechnology's score of 0.10 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.
PDS Biotechnology has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500.
Summary
Amylyx Pharmaceuticals beats PDS Biotechnology on 11 of the 16 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
